MedTrace Logo

Guidewire Management in ERCP

NCT05219123 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7461

Last updated 2024-12-20

No results posted yet for this study

Summary

Intra-procedural guidewire management is a parameter whose impact remains incompletely understood in terms of its association with post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). Inadvertent guidewire cannulation of the pancreatic duct (PD) when attempting common bile duct (CBD) cannulation is recognized as a risk factor for PEP. However, to date, no studies have assessed whether a single PD wire cannulation is associated with a higher PEP risk compared to no PD cannulations. Similarly, the relationship between each additional PD cannulation and the incremental magnitude of PEP risk remains unclear. In this study, the investigators will aim to assess whether a single inadvertent PD cannulation (versus no PD cannulation) is associated with an increased risk of PEP (the primary outcome).

Conditions

  • ERCP

Interventions

OTHER

ERCP with no PD cannulation

ERCP with no PD cannulation

OTHER

ERCP with single PD cannulation

ERCP with single PD cannulation

Sponsors & Collaborators

  • McGill University

    collaborator OTHER

  • University of Ottawa

    collaborator OTHER

  • Queen's University

    collaborator OTHER

  • Halton Health (Oakville)

    collaborator UNKNOWN

  • Island Health, Victoria, BC

    collaborator OTHER

  • University of Calgary

    lead OTHER

Principal Investigators

  • Nauzer Forbes, MD MSc · University of Calgary

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-20
Primary Completion
2024-12-09
Completion
2024-12-09

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05219123 on ClinicalTrials.gov